The study drug is a potential new treatment for Idiopathic Pulmonary Fibrosis (IPF)
The study aims to evaluate the safety and efficacy of a new potential treatment for thrombocytopenia, exploring the potential future use for increasing platelet counts in Caucasian individuals with this condition. Previous studies led to the study medication becoming approved internationally since 2005, achieving positive outcomes for increasing platelets in patients.
Thrombocytopenia is the name for a condition for when a person has a low platelet count. The condition can be caused by various reasons, including immune disorders, infections, and certain medications. Platelets are crucial for blood clotting, and a deficiency can lead to increased bleeding and bruising, making it a significant health concern.
The results of this study will provide critical data, essential for the development and approval of new therapeutic agents for the wider population across the world.
The trial has been approved by an independent ethics committee and eligible participants will be reimbursed for their time.
Call us on 1800 243 733 to discuss your eligibility today!